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Proper cell-cycle transitions are driven by waves of
ubiquitin-dependent degradation of key regulators
by the anaphase-promoting complex (APC) and
Skp1-Cullin1-F-box (SCF) E3 ubiquitin ligase com-
plexes. But precisely how APC and SCF activities
are coordinated to regulate cell-cycle progression
remains largely unclear. We previously showed that
APC/Cdh1 earmarks the SCF component Skp2 for
degradation. Here, we continue to report that
SCFb-TRCP reciprocally controls APC/Cdh1 activity
by governing Cdh1 ubiquitination and subsequent
degradation. Furthermore, we define both cyclin A
and Plk1, two well-known Cdh1 substrates, as up-
streammodifying enzymes that promote Cdh1 phos-
phorylation to trigger Cdh1 ubiquitination and subse-
quent degradation by SCFb-TRCP. Thus, our work
reveals a negative repression mechanism for SCF
to control APC, thereby illustrating an elegant dual
repression systembetween these two E3 ligase com-
plexes to create the ordered cascade of APC and
SCF activities governing timely cell-cycle transitions.
INTRODUCTION
As defective regulation of the cell cycle leads to genomic insta-
bility and ultimately cancer development (Harper et al., 2002;
Nakayama et al., 2001), identification of key regulatory mecha-
nisms may shed light on mechanisms that initiate and promote
carcinogenesis. There is mounting evidence suggesting that
proper cell-cycle transitions are driven by coordinated waves
of ubiquitin-dependent degradation of key cell-cycle regulators
by the anaphase-promoting complex (APC) and Skp1-Cullin1-
F-box (SCF) E3 ubiquitin ligase complexes (Harper et al., 2002;
Nakayama et al., 2001; Nakayama and Nakayama, 2005). How-
ever, molecular mechanisms mediating ordered SCF and APC
activities have not been fully characterized. Previously, we andothers demonstrated that APC/Cdh1 ubiquitinates and thus tar-
gets the SCF component Skp2 for degradation in early G1 phase
(Bashir et al., 2004; Wei et al., 2004). This was the first illustration
of the crosstalk between SCF and APC, which has shed light
on the tight regulatory mechanisms of coordinated cell-cycle
progression, gaining important insight as to why SCF and APC
activities are mutually exclusive during the cell cycle (Nakayama
et al., 2001).
Cdh1 is one of the substrate adaptors for the APC E3 ligase
complex that directly interacts with APC/Cdh1 substrates via
Destruction Boxes (D-box) or KEN Boxes (Harper et al., 2002;
Peters, 2006). Because Cdh1 is a crucial regulator of cell-cycle
progression, its function is tightly controlled in vivo. Cdh1 asso-
ciates with the APC core complex in the late M phase to activate
APC/Cdh1, which plays a critical role in mitosis exit by
completing the degradation of Securin and cyclin B (Peters,
2006). On the other hand, APC/Cdh1 activity is terminated by
multiple mechanisms including cyclin-A-dependent phosphory-
lation of Cdh1 that dissociates Cdh1 from the APC core complex
to ensure a timely transition from G1 to S phase (Lau et al., 2013;
Lukas et al., 1999; Sørensen et al., 2001). Notably, Cdh1 protein
levels were significantly reduced in the late G1 phase (Benmaa-
mar and Pagano, 2005), suggesting that its stability might be
under tight regulation during the G1 to S cell-cycle transition.
Although Cdh1 undergoes self-ubiquitination and degradation
(Listovsky et al., 2004), this seems to not account for the low
Cdh1 abundance during the late G1 phase; as in this specific
cell-cycle phase, Cdh1 is inactivated by Cdk2/cyclin-A- and/or
Cdk2/cyclin-E-dependent phosphorylation (Keck et al., 2007;
Lau et al., 2013; Lukas et al., 1999). Therefore, the molecular
mechanism(s) underlying the timely degradation of Cdh1 at the
G1-S boundary still remains largely elusive.
Given that APC negatively regulates the SCF complex (Bashir
et al., 2004;Wei et al., 2004), it is an intriguing possibility that SCF
may reciprocally repress APC, thereby generating a negative
feedback loop. In support of this theory, emerging evidence
has demonstrated that Cdh1 is unstable, and Cullin-1 is involved
in its degradation (Benmaamar and Pagano, 2005). However, the
identity of the specific F-box protein that binds Cullin-1 and pro-
motes Cdh1 degradation remains elusive. To date, whereas theCell Reports 4, 803–816, August 29, 2013 ª2013 The Authors 803
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Figure 1. Cullin 1 Controls Cdh1 Stability
(A and B) Cdh1 expression levels fluctuate across the cell cycle. (A) Immunoblot (IB) analysis of U2OS cells synchronized by growth in hydroxyurea and then
released for the indicated periods of time. (B) IB analysis of HeLa cells arrested in theMphase by nocodazole treatment and then released back into the cell cycle.
FACS analysis revealed that cells entered the S phase approximately 12 hr postnocodazole release (see also Figures 6B, 6C, 6E, and 6F).
(C) Induced overexpression of a dominant-negative form of Cullin 1 (N252-Cullin 1) results in upregulation of Cdh1 and other known SCF substrates.
(D) Expression of a dominant-negative (DN) Cullin 1 results in an increase in Cdh1 abundance. IB analysis of whole-cell lysates (WCL) derived from HeLa cells
transfected with the indicated constructs encoding various dominant-negative (DN) forms of Cullin family of proteins.
(E and F) Cullin 1 interacts with Cdh1 in vivo. (E) IB analysis of WCL and immunoprecipitates (IP) derived from 293T cells transfected with HA-Cdh1 and the
indicated Myc-tagged Cullin family of proteins. Thirty hours posttransfection, cells were pretreated with the proteasome inhibitor MG132 (10 mM) for 10 hr before
harvesting to detect the HA-Cdh1 and Myc-Cullin interaction. (F) IB analysis of WCL and anti-Cdh1 IP derived from HeLa cells. Cells were treated with the
proteasome inhibitor MG132 (10 mM) overnight before harvesting to detect the interaction of endogenous Cdh1 with the indicated proteins.
(G) Depletion of endogenous Cullin 1 results in an increase in Cdh1 protein levels. IB analysis of WCL derived from HeLa cells infected with the indicated lentiviral
shRNA constructs. Twenty hours postinfection, cells were selected with 1 mg/ml puromycin for 72 hr to eliminate noninfected cells.
See also Figure S1.F-box protein, Emi-1, has been shown to repress APC/Cdh1
activity (Hsu et al., 2002), it does so not by affecting Cdh1 stabil-
ity but rather by blocking the ability of Cdh1 to degrade its phys-
iological substrates (Miller et al., 2006). Here, we report that the
F-box protein, b-TRCP, regulates Cdh1 degradation. We further
defined that sequential phosphorylation of Cdh1 by cyclin A and
Plk1 triggers b-TRCP-mediated Cdh1 ubiquitination and subse-
quent degradation. Therefore, in addition to APC-mediated sup-
pression of SCF by targeting Skp2 for degradation, there also
exists a negative repression mechanism by which the SCF com-
plex controls APC E3 ligase activity.
RESULTS
Cullin 1 Controls Cdh1 Stability
Using synchronization methods, we found that, consistent with a
previous report (Benmaamar and Pagano, 2005), Cdh1 expres-804 Cell Reports 4, 803–816, August 29, 2013 ª2013 The Authorssion levels fluctuate over the cell cycle with lower expression
levels during the S phase (Figures 1A and 1B). Because the
APC/Cdh1 E3 ubiquitin ligase activity is inhibited by Cdk2/cyclin
A in the late G1/S phase, these results indicate that an as-yet-un-
identified E3 ligase, other than Cdh1 itself (Listovsky et al., 2004),
might be responsible for mediating the degradation of Cdh1
during this period. In keeping with this notion, compared to
wild-type (WT)-Cdh1, DFizzy-Cdh1, and DC-box-Cdh1 that are
deficient in associating with the APC core complex (Figures
S1A–S1C), thereby impaired in self-ubiquitination, are still rela-
tively unstable during the G1 phase (Figure S1D). Asmultisubunit
Cullin-Ring complexes comprise the largest known family of E3
ligases (Petroski andDeshaies, 2005), we first examinedwhether
a specific Cullin-Ring complex was involved in regulating Cdh1
degradation. Consistent with a previous report (Benmaamar
and Pagano, 2005), inactivation of Cullin 1, by overexpressing
a dominant-negative Cullin 1 mutant, significantly increased
the abundance of endogenous Cdh1 (Figure 1C). More impor-
tantly, ectopic overexpression of other dominant-negative forms
of Cullins did not notably affect Cdh1 expression in HeLa cells
(Figure 1D), arguing for a specific role of Cullin 1 in governing
Cdh1 stability (Figure S1E). Consistently, we detected a specific
interaction between Cdh1 and Cullin 1, but not other Cullin family
members (Figure 1E). Furthermore, we detected an interaction
between endogenous Cdh1 and Cullin 1 (Figure 1F). In further
support of a physiological role for Cullin 1 in Cdh1 stability con-
trol, depletion of endogenous Cullin 1, but not endogenous Cullin
2 that does not associate with Cdh1 in vivo (Figure 1E), led to a
significant increase in Cdh1 abundance (Figures 1G and S1F).
These results altogether suggest the involvement of the SCF
type of E3 ligase complex in Cdh1 protein stability control.
SCFb-TRCP Negatively Regulates the Stability of Cdh1
Although Cullin 1 has been reported to control Cdh1 stability
(Benmaamar and Pagano, 2005), the identity of the specific
F-box protein that binds with Cullin 1 to form a functional SCF
type of E3 ligase complex and promotes Cdh1 degradation re-
mains unknown. Because Cdh1 expression fluctuates during
the cell cycle, we investigated whether Cdh1 interacts with a
panel of F-box proteins with known functions in cell-cycle regu-
lation (Nakayama andNakayama, 2005). In addition to the known
Cdh1 interaction with its substrate Skp2, we only detected a
specific interaction between Cdh1 and b-TRCP1, but not with
other F-box proteins we examined (Figure 2A). In support of
b-TRCP as the specific F-box protein capable of regulating
Cdh1 degradation, we detected an interaction between endoge-
nous Cdh1 and b-TRCP1 (Figure 2B).
Furthermore, depletion of b-TRCP1 and b-TRCP2 in
asynchronized HeLa cells led to a significant increase in
steady-state levels of Cdh1 (Figure 2C), which can be rescued
by expression of engineered small-hairpin-RNA (shRNA)-resis-
tant b-TRCP1, highlighting the specificity of the shb-TRCP treat-
ment to result in an elevation of Cdh1 expression (Figure 2D).
Compared to the control small-interfering-RNA (siRNA)-treated
HeLa cells, degradation of Cdh1 in the late G1-S phase was
largely abolished after depletion of b-TRCP (Figures 2E and
2F). Likewise, sib-TRCP treatment resulted in decreased expres-
sion of the Cdh1 substrates cyclin A and Cdc20, suggesting a
delayed entry into the S phase (Figures 2E). Moreover, depletion
of endogenous b-TRCP1 and b-TRCP2 resulted in an increase in
the abundance of both WT-Cdh1 and DFizzy-Cdh1, indicating
that SCFb-TRCP possibly governs Cdh1 stability independent of
Cdh1 self-ubiquitination (Figure S2A).
Notably, depletion of b-TRCP did not significantly increase
Cdh1 mRNA levels, indicating that the observed increase in
Cdh1 abundance may be mainly through a posttranslational
mechanism(s) (Figure 2G). However, depletion of b-TRCP2, but
not b-TRCP1, led to a moderate decrease in Cdh1 mRNA levels,
but the biological significance of this change currently remains
unclear (Figure 2G). Furthermore, depletion of b-TRCP1 resulted
in an approximately 1.7-fold induction of b-TRCP2 mRNA levels
(Figure 2I), which might be in part explained by a possible
compensation effect. Although b-TRCP1 and b-TRCP2 have
been indicated to possess similar enzymatic functions in various
in vitro biochemical reactions (Cardozo andPagano, 2004; Fuchset al., 2004), there is emerging evidence indicating that their
cellular localization or tissue specificity might differ significantly
(Lassot et al., 2001; Seo et al., 2009). In addition, b-TRCP1 and
b-TRCP2 have been found to respond to different upstream sig-
nals (Spiegelman et al., 2001, 2002). Hence, additional studies
are required to fully understand the underlying mechanisms
and biological outputs for the observed induction of b-TRCP2
upon acute depletion of b-TRCP1. Importantly, in support of a
role for b-TRCP in modulating Cdh1 stability, we demonstrated
that increased Cdh1 expression in the late G1-S phase following
b-TRCP depletion was in part due to prolonged Cdh1 half-life
(Figures S2B and S2C). Moreover, Cdh1 half-life was greatly
reduced following DNAdamage (Liu et al., 2008), whereas deple-
tion of b-TRCP extended the half-life of Cdh1 in this experimental
condition (Figures 2J and 2K), confirming the important physio-
logical role of b-TRCP in regulating Cdh1 turnover.
Plk1 and Cdk2/Cyclin A Synergistically Promote the
Interaction between Cdh1 and b-TRCP1
Previous studies frommultiple groups showed that most b-TRCP
substrates contain aDSGX(2-4)S degron sequence (Cardozo and
Pagano, 2004), which must be phosphorylated in order to effi-
ciently interactwithb-TRCP.However, wedid not findany canon-
ical degron sequence within Cdh1. Consistent with Cdh1 being a
Cdk2/cyclinA substrate (Lukaset al., 1999;Sørensenet al., 2001),
depletion of cyclin A led to an obvious upregulation of endoge-
nous Cdh1 levels in U2OS cells (Figure S3A). Using in vitro kinase
assays, we showed that, in addition to the four previously identi-
fied Ser/Thr sites (Lukas et al., 1999), there are two possible addi-
tional putative Cdk2/cyclin A sites at the N terminus of Cdh1 (Fig-
ures 3A and 3B). The in vivo phosphorylation of these sites was
further confirmed by mass spectrometry analysis (Dephoure
et al., 2008). The conserved cyclin A binding Arg-Val-Leu (RVL)
motif at the C terminus of Cdh1 is also known to be critical for
its interaction with cyclin A (Sørensen et al., 2001). Interestingly,
mutation of the RVLmotif or the putative cyclin A phosphorylation
sites greatly reduced the interaction between b-TRCP1 andCdh1
in vivo (Figure 3C). Furthermore, depletion of b-TRCP led to an in-
crease in the abundance of ectopically expressed WT, but not
mutant forms of Cdh1 (Figures 3D and S3B). Taken together,
these results indicate that phosphorylation of Cdh1 by the
Cdk2/cyclin A complex not only is responsible for terminating
the E3 ligase activity of Cdh1 (Lukas et al., 1999; Sørensen
et al., 2001), but may also serve as a degradation signal for Cdh1.
Intriguingly, however, incubation of GST-Cdh1 with purified
Cdk2/cyclin A did not promote the interaction between GST-
Cdh1 and b-TRCP1 in vitro (Figure 3E), suggesting that Cdk2/
cyclin A is not the only regulatory kinase, and possibly additional
phosphorylation events mediated by kinases other than Cdk2/
cyclin A may be required to trigger the interaction of Cdh1 with
b-TRCP (Figure 7A). Upon a closer examination of the Cdh1 pro-
tein sequence, it was revealed that Cdh1 contains a suboptimal
degron closely resembling the DSGxxS motif, which contains
Ser146 (DDGNDVpSP) that may mediate the timely degradation
of Cdh1 following UV irradiation (Figure 3F) (Liu et al., 2008).
Because both Ser138 and Ser146 appear to be potential Plk1
phosphorylation sites that closely resemble the consensus sub-
strate sequence for Plk1 ([D/E]-X[pS/pT]-X-X-[D/E]) (DephoureCell Reports 4, 803–816, August 29, 2013 ª2013 The Authors 805
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Figure 2. SCFb-TRCP Negatively Regulates the Stability of Cdh1
(A and B) Cdh1 interacts with b-TRCP1 in vivo. (A) Immunoblot (IB) analysis of whole-cell lysates (WCL) and immunoprecipitates (IP) derived from 293T cells
transfected with constructs encoding the indicated HA-tagged F-box proteins. Thirty hours posttransfection, cells were pretreated with the proteasome inhibitor
MG132 (10 mM) for 10 hr before harvesting to detect the interaction of endogenous Cdh1 with the indicated HA-tagged F-box proteins. (B) IB analysis of WCL and
anti-Cdh1 IP derived from 293T cells. Cells were treated with the proteasome inhibitor MG132 (10 mM) overnight before harvesting to detect the interaction
between endogenous Cdh1 and b-TRCP1 proteins.
(C) Depletion of endogenous b-TRCP leads to an increase in endogenous Cdh1 abundance. IB analysis of WCL derived from HeLa cells infected with the
indicated lentiviral shRNA constructs. Twenty hours postinfection, cells were selected with 1 mg/ml puromycin for 72 hr to eliminate noninfected cells.
(D) Expression of engineered shRNA-resistant versions of b-TRCP1 in shb-TRCP-treated cells suppressed Cdh1 upregulation. IB analysis of 293T cells trans-
fected with the indicated shRNA constructs. Where indicated, Flag-b-TRCP1* or Flag-b-TRCP1**, which is engineered to resist shb-TRCP1 or shb-TRCP1+2,
respectively, was included in the transfection.
(E and F) Depletion of endogenous b-TRCP by siRNA treatment results in elevated Cdh1 expression in late G1/S phases. (E) HeLa cells were transfected with
control or b-TRCP1+2 siRNA oligos, arrested with nocodazole and then released back into the cell cycle for immunoblot analysis. Cdc25A was blotted as a
positive control of a reported b-TRCP substrate. (F) Quantification of the band intensities in (E). The intensities of Cdh1 bands were normalized to tubulin, then
normalized to the t = 0 time point. Data are represented as mean ± SD, n = 3, and *p < 0.05 (Student’s t test).
(legend continued on next page)
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et al., 2008; Nakajima et al., 2003) (Figures 3F and S3C), we per-
formed in vitro kinase assays to confirm that both Ser138 and
Ser146 are Plk1 phosphorylation sites (Figure 3G). However,
we detected residual Plk1-dependent phosphorylation even in
the 6A/S138A/S146A mutant (Figure 3G), indicating that,
besides Ser138 and Ser146, there might be additional Plk1 sites
present in Cdh1. Nonetheless, these results prompted us to
further study a potential role for Plk1 in regulating Cdh1 stability.
SCFb-TRCP Promotes the Ubiquitination and Degradation
of Cdh1 in a Plk1-Dependent Manner
In agreement with a role for Plk1 in Cdh1 stability control, we de-
tected an interaction between endogenous Cdh1 and Plk1 (Fig-
ure 2B) and further found that depletion of endogenous Plk1, by
various shRNA constructs, led to increased levels of Cdh1 (Fig-
ures 3H and S3D), which correlates with an extended Cdh1 half-
life (Figures S3E and S3F). Moreover, alanine replacement of the
Ser138 and Ser146 residues in Cdh1 abolished the elevation of
Cdh1 induced by depletion of b-TRCP, arguing for a critical
role for Plk1 in b-TRCP-mediated Cdh1 degradation (Figure 4A).
More importantly, using in vitro peptide pull-down assays, we
found that biotinylated Cdh1 peptides interacted with 35S-
labeled b-TRCP1 only when Ser146 and/or Ser138 were
phosphorylated (Figure 4B). In addition, Plk1-mediated phos-
phorylation of GST-Cdh1 resulted in a significant increase in
b-TRCP-mediated binding with bacterially purified recombinant
GST-Cdh1 in vitro (Figure S4A). Importantly, in keeping with
the notion that prior phosphorylation of substrates is critical for
their recognition by b-TRCP (Cardozo and Pagano, 2004; Fuchs
et al., 2004), these identified Cdk2/cyclin A and Plk1 phosphor-
ylation sites were crucial for b-TRCP-dependent ubiquitination
of Cdh1 both in vivo and in vitro (Figures 4C and S4B). Consistent
with the critical role of Ser146 as part of the DSGxxS degron
sequence (Figures 4B and S3C) mediating the degradation of
Cdh1 by b-TRCP, coexpression of b-TRCP and Plk1 significantly
decreased the half-life of WT, but not the S138A/S146A version
of Cdh1 (Figures 4D and 4E). Thus, these results coherently sup-
port a critical role for Plk1 in governing b-TRCP-mediated Cdh1
ubiquitination. However, the potential presence of additional
Plk1 sites besides S138 and S146 in Cdh1 (Figure 3G) indicates
that similar to many well-characterized b-TRCP substrates,
including Gli3 (Wang and Li, 2006) and Mdm2 (Inuzuka et al.,
2010), there might be multiple suboptimal degrons mediating
the ubiquitination of Cdh1 by SCFb-TRCP.
Phosphorylation of Cdh1 by Cdk2/Cyclin A Creates Plk1
Binding Sites for the Subsequent Phosphorylation of
Cdh1 by Plk1
The substrate specificity of Plk1was previously determined to be
mediated largely by the two tandem Polo-Box domains (PBD) at(G–I) Depletion of endogenous b-TRCP does not significantly affect Cdh1 mRNA
level changes in Cdh1 (G), b-TRCP1 (H), and b-TRCP2 (I) after shRNA treatment
(J and K) Depletion of endogenous b-TRCP extends the half-life of endogenous C
and then treated with etoposide to induce DNA damage. Afterward, Cdh1 half-
intensities in (J). The intensities of Cdh1 bands were normalized to tubulin and the
and *p < 0.05 (Student’s t test).
See also Figure S2.the C terminus of Plk1, which preferentially bind to the SpS/pTP
motif that is also called PBD binding motif (Elia et al., 2003a,
2003b). Cdh1was reported to be phosphorylated byCdk2/cyclin
A at the S40, S151, S163, and T121 sites (Lukas et al., 1999),
among which both the S40 and T121 sites match the stringent
PBD binding motif (Figure 3A). Thus, we next explored whether
phosphorylation of Cdh1 by Cdk2/cyclin A creates possible
Plk1 binding sites for subsequent phosphorylation of Cdh1 at
Ser146 by Plk1. In support of this notion, mutating Cdh1 at either
the cyclin A interaction site (RVL/AAA) or the putative Cdk2/
cyclin A sites impaired the interaction between Cdh1 and Plk1
(Figures 5A and 5B). Using in vitro kinase assays, we demon-
strated that the impaired interaction might be partly due to
reduced phosphorylation of the PBD bindingmotifs in Cdh1 (Fig-
ure 5C, middle panel). In keeping with this result, pretreatment of
GST-Cdh1 with purified Cdk2/cyclin A, but not Plk1 could
promote a significant increase in phosphorylation of the PBD
binding motifs in vitro (Figure S5A, middle panel). As such,
pretreatment of GST-Cdh1 with cyclin A/Cdk2 induced the inter-
action of Plk1 with Cdh1 in vitro (Figure 5B) as well as Plk1-
dependent phosphorylation of Cdh1 in vitro (Figure 5C, top
panel) and in vivo (Figure 5D). Consistent with these observa-
tions, sequential kinase treatment of GST-Cdh1with Cdk2/cyclin
A and Plk1 augmented the interaction between Cdh1 and
b-TRCP1 in vitro (Figure 5E). Importantly, Plk1-dependent phos-
phorylation of Cdh1 (Figures 5C and 5D), as well as the interac-
tion between Plk1 and Cdh1 (Figure 5B), and the interaction
between Cdh1 and b-TRCP1 (Figure 5E), were all abolished by
Ala replacements of the characterized cyclin A/Cdk2 sites of
Cdh1. These data indicate that Cdk2/cyclin-A-mediated Cdh1
phosphorylation is a critical step for Plk1 to interact with, and
phosphorylate Cdh1, which subsequently induces b-TRCP bind-
ing to Cdh1 (Figure 7A).
In order to obtain more insights into how Plk1-mediated phos-
phorylation of Ser146 affects Cdh1 stability, we developed a
specific antibody against pSer146-Cdh1 (Figure S5B). Impor-
tantly, inactivating endogenous Plk1 by either shRNA (Figure 5F)
or the pharmacological Plk1 inhibitor, BI2536 (Steegmaier et al.,
2007) (Figure 5G), led to a significant reduction in phosphoryla-
tion of Cdh1 at Ser146, arguing that Ser146 is a physiological
Plk1 site in vivo. In further support of a critical role of Ser146 in
b-TRCP1-mediated degradation of Cdh1, we found that endog-
enous b-TRCP1 preferentially interacts with endogenous Cdh1
that is phosphorylated at Ser146 (Figure 5H), and depletion of
b-TRCP (Figure 5I) or inhibiting the 26S proteasome by MG132
(Figure 5J) resulted in elevated phosphorylation of Ser146-
Cdh1 in HeLa cells.
In light of these findings, and given that both cyclin A and Plk1
are themselves Cdh1 substrates, it appears that there exists an
elegant negative feedback loop within the cell cycle that ensureslevels. Real-time RT-PCR analysis to examine the relative mRNA expression
s as described in (C). Data are represented as mean ± SD, n = 3.
dh1. (J) HeLa cells were transfected with control or b-TRCP1+2 siRNA oligos
life was measured using cycloheximide (CHX). (K) Quantification of the band
n normalized to the t = 0 time point. Data are represented as mean ± SD, n = 3,
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Figure 3. Plk1 and Cdk2/Cyclin A Synergistically Promote the Interaction between Cdh1 and b-TRCP1
(A) Schematic diagram of putative Cdk2/cyclin A phosphorylation sites on Cdh1 and Cdh1 mutants used in this study.
(B) Cdk2/cyclin A phosphorylates Cdh1 in vitro. In vitro kinase assays to pinpoint the major Cdk2/cyclin-A-mediated phosphorylation sites in Cdh1. GST-S138A/
S146A-Cdh1 was also included in the in vitro kinase assay to illustrate that both Ser138 and Ser146 are major phosphorylation sites mediated by Plk, but not by
Cdk2/cyclin A in vitro (see also Figures 2F and 2G).
(C) Phosphorylation of Cdh1 by Cdk2/cyclin A is important for the interaction of Cdh1 with b-TRCP1 in vivo. Flag-tagged b-TRCP1 and various Myc-tagged Cdh1
constructs were expressed in HeLa cells and IPs were performed accordingly. Cells were treated with the proteasome inhibitor MG132 (10 mM) overnight before
harvesting to detect the interaction between Flag-b-TRCP1 and Myc-Cdh1 proteins.
(D)Mutation of the Cdk2/cyclin-A-mediated phosphorylation sites in Cdh1 attenuates shb-TRCP-induced Cdh1 stabilization. IB analysis of HeLa cells transfected
with the indicated shRNA constructs together with the indicated Myc-tagged Cdh1 constructs and jellyfish GFP (eGFP) as a transfection control.
(E) Plk1- but not Cdk2/cyclin-A-mediated phosphorylation of Cdh1 promotes the interaction between b-TRCP and Cdh1 in vitro. Autoradiograms show binding of
35S-labeled b-TRCP1 with the indicated GST-Cdh1 proteins (GST protein as a negative control) in the presence of Cdk2/cyclin A and/or Plk1.
(legend continued on next page)
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Figure 4. SCFb-TRCP Promotes the Ubiquitination and Degradation of Cdh1 in a Plk1-Dependent Manner
(A)Mutation of Plk1-mediated phosphorylation sites in Cdh1 attenuates shb-TRCP-induced Cdh1 stabilization. Immunoblot (IB) analysis of HeLa cells transfected
with the indicated shRNA constructs together with the WT or the S138A/S146A mutant form of Cdh1.
(B) Plk1-mediated phosphorylation of Cdh1 at Ser138 and Ser146 is important for interaction between Cdh1 and b-TRCP1 in vitro. Autoradiograms showing
recovery of 35S-labeled b-TRCP1 bound to indicated biotinylated peptides.
(C) In vivo ubiquitination assays illustrate that SCFb-TRCP promotes Cdh1 ubiquitination in a cyclin A/Plk1-dependent manner.
(D and E) Mutation of Plk1-mediated phosphorylation sites in Cdh1 increases the half-life of Cdh1. (D) HeLa cells were transfected with the indicated HA-Cdh1
constructs together with the Myc-b-TRCP1 and Flag-Plk1 plasmids. Twenty hours posttransfection, cells were split into 60 mm dishes and, after another 20 hr,
treated with 20 mg/ml cycloheximide (CHX). At the indicated time points, whole-cell lysates were prepared for immunoblot analysis. (E) Quantification of the band
intensities in (D). Cdh1 band intensity was normalized to tubulin and then normalized to the t = 0 controls.
See also Figure S4.timely inactivation of APC/Cdh1 prior to S phase onset (Fig-
ure 7B). Interestingly, in support of a negative role for both
Cdk2/cyclin A and Plk1 in Cdh1 stability control, both the Cdk2
inhibitor roscovitine (Figure 5K) and the Plk1 inhibitor BI2536
(Figure 5L) led to an increase in Cdh1 abundance, and a subse-(F) Schematic diagram of putative Plk1-mediated phosphorylation sites in Cdh1.
(G) Mapping the Plk1-mediated phosphorylation sites in Cdh1. In vitro kinase as
(H) Depletion of endogenous Plk1 stabilizes Cdh1. IB analysis of WCL derived fro
hours postinfection, cells were selected with 1 mg/ml puromycin for 72 hr to elim
See also Figure S3.quent decrease in the Cdh1 substrate Plk1. Furthermore, rosco-
vitine or BI2536-induced decrease of Plk1 was impaired in
Cdh1-deficient cells (Figures 5K and 5L). Notably, as Cdh1-defi-
cient cells displayed elevated expression of both the Plk1 and
cyclin A oncoproteins, compared with shGFP-treated cells,says depicting putative Plk1 phosphorylation sites in Cdh1 (shown in F).
m U2OS cells infected with the indicated lentiviral shRNA constructs. Twenty
inate noninfected cells.
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Figure 5. Phosphorylation of Cdh1 by Cdk2/Cyclin A Creates Plk1 Binding Sites for Subsequent Phosphorylation of Cdh1 at Ser146
by Plk1
(A and B) Cdk2/cyclin-A-mediated phosphorylation of Cdh1 is important for the interaction between Plk1 and Cdh1. (A) Immunoblot (IB) analysis of whole-cell
lysates (WCL) and immunoprecipitates (IP) derived from 293T cells transfected with HA-Plk1 and the indicated Cdh1 constructs. Thirty hours posttransfection,
cells were pretreated with the proteasome inhibitor MG132 (10 mM) for 10 hr before harvesting to detect the interaction betweenMyc-Cdh1 and HA-Plk1 proteins.
(B) Autoradiograms showing the recovery of 35S-labeled Plk1 to the indicated GST-Cdh1 proteins (GST protein as a negative control) incubated with Cdk2/cyclin
A before the in vitro pull-down assays.
(C) Cdk2/cyclin-A-mediated phosphorylation of Cdh1 primes for the subsequent phosphorylation of Cdh1 by Plk1 in vitro. Purified Plk1 and/or Cdk2/cyclin A
proteins were incubated with 3 mg of the indicated GST-Cdh1 proteins in the presence of g-32P-ATP. The kinase reaction products were resolved by
SDS-PAGE, and phosphorylation was detected by autoradiography (top panel). The phosphorylation in the PBD motif(s) was detected by IB analysis (middle
panel).
(D) Phosphorylation of Cdh1 by Cdk2/cyclin A creates Plk1 binding motifs in Cdh1. IB analysis of WCL and IP derived from 293T cells transfected with the
indicated Myc-Cdh1 constructs. Thirty hours posttransfection, cells were pretreated with the proteasome inhibitor MG132 (10 mM) for 10 hr before harvesting to
stabilize the phosphorylated Myc-Cdh1 protein.
(legend continued on next page)
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shCdh1-treated cells were muchmore sensitive to the treatment
of roscovitine and/or BI2536 (Figure S5C), a phenotype recently
described as ‘‘oncogene addiction’’ (Sharma and Settleman,
2007). Our results indicate that further preclinical studies are
warranted to explore the synergistic usage of Cdk2 and Plk1
inhibitors in anticancer treatment, especially for Cdh1-deficient
patients.
SCFb-TRCPNegatively Regulates Cdh1Stability to Ensure
Proper Cell-Cycle Progression
Next, we intended to determine the biological significance of
b-TRCP1-mediated ubiquitination and subsequent degradation
of Cdh1. To this end, concomitant with b-TRCP1 or Plk1 deple-
tion, there was an increase in Cdh1 abundance that correlated
with elevated abundance of pSer146-Cdh1 (Figure S6A), and a
reduction in both cyclin B and Geminin expression levels in the
late G1 phase, which resulted in delayed S phase entry as judged
by fluorescence-activated cell sorting (FACS) analysis (Figures
6A–6C and S6B). Consistent with a previous report (Oshimori
et al., 2006), depletion of Plk1 also resulted in an impairedmitotic
exit (Figures 6B, 6C, and S6B). In further support of our
hypothesis that Cdh1 dysregulation causes b-TRCP-depletion-
mediated cell-cycle defects, compared to EV or WT-Cdh1-
expressing cells, tetracycline (Tet)-induced expression of
nondegradable Cdh1 mutants (4A-Cdh1 and S138A/S146A-
Cdh1) phenocopies the depletion of b-TRCP, leading to a
retarded S phase entry (Figures 6D–6F). Notably, further studies
revealed that, compared to WT-Cdh1, the half-lives of both 4A-
Cdh1 and S138A/S146A-Cdh1 were extended in the G1 phase
(Figures S6C–S6F), arguing for a critical role for these phosphor-
ylation sites in triggering the timely degradation of Cdh1 by
b-TRCP in the G1 phase.
On the other hand, Tet-inducible expression of Plk1 resulted in
the increased degradation of Cdh1 and a subsequent increase in
Cdh1 substrates (Figure S6G). Importantly, our findings could
also be reproduced in silico using a mathematical (ordinary dif-
ferential equation [ODE]) model described previously (Conradie
et al., 2010). Specifically, when Cdh1 degradation or phosphor-
ylation rate is set to zero, the cell-cycle duration is increased,
whereas cyclin A and Cdc20 expression levels are decreased
(Figure S6H). Notably, the simulated results (Figure S6H) match(E) Phosphorylation of Cdh1 by Plk1 enhances the binding between Cdh1 and b-T
indicated GST-Cdh1 proteins (GST protein as a negative control) incubated wit
proteins were treated with Cdk2/cyclin A prior to the in vitro Plk1 kinase assay.
(F and G) Inhibition of Plk1 reduces the phosphorylation of Cdh1 at Ser146 in vi
lentiviral shRNA constructs. Twenty hours postinfection, cells were selected with 1
derived from HeLa cells treated with the Plk inhibitor BI2536 (25 nM) for 6 hr bef
(H) The in vivo interaction between Cdh1 and b-TRCP is phosphorylation depende
negative control). Cells were treated with the proteasome inhibitor MG132 overni
lysates were treated with the l-phosphatase before immunoprecipitation.
(I and J) Inhibition of Cdh1 degradation results in elevated phosphorylation on Se
cells infected with the indicated lentiviral shRNA constructs. Twenty hours pos
noninfected cells. (J) IB analysis of WCL derived from HeLa cells treated with the
(K) Inhibition of Cdk2/cyclin A increases Cdh1 levels. IB analysis of WCL derive
treated with the Cdk2 inhibitor roscovitine (20 mM) for the indicated time periods
(L) Inhibition of Plk1 increases Cdh1 levels. IB analysis of WCL derived from shCdh
Plk inhibitor BI2536 (25 nM) for the indicated time periods before harvesting.
See also Figure S5.the critical findings that have been observed in our experimental
settings (Figures 6D–6F). Furthermore, consistent with the
notion that many key cell-cycle regulators play a critical role in
differentiation (Fasano et al., 2007; Hong et al., 2009; Janzen
et al., 2006), the nondegradable S138A/S146A mutant of Cdh1
displayed elevated ability in inhibiting Xenopus oocyte develop-
ment (Figures 6G and 6H). Therefore, these results further illus-
trate the biological significance of the SCFb-TRCP -Cdh1 axis in
cell-cycle regulation (Figures 7 and S7L). For more details, see
also Extended Results.
DISCUSSION
We and others previously showed that APC/Cdh1 degrades
Skp2 in the early G1 phase (Bashir et al., 2004; Wei et al.,
2004), indicating that early cell-cycle events set the tempo and
ensure the timely achievement of later events. However, rela-
tively little is known about the upstream pathways that control
Cdh1’s stability and E3 ligase activity. Here, we report that recip-
rocally SCFb-TRCP could suppress APC by promoting Cdh1 for
ubiquitination and subsequent degradation. This work demon-
strates that cell-cycle progression behaves less as a linear
pathway and more like an interwoven network, or coupled oscil-
latory modules (Lu and Cross, 2010).
By elucidating the dual repressive mechanism between SCF
and APC, we will likely gain a better understanding of how the
orchestration of E3 ligase activities controls the timely degrada-
tion of key cell-cycle regulators to govern proper cell-cycle pro-
gression. More importantly, we identified the Cdh1 substrates
cyclin A and Plk1 as the modifying enzymes that govern Cdh1
stability. In early G1 phase where APC/Cdh1 is mostly active,
APC/Cdh1 plays a dominant role, promoting the degradation
of its substrates including cyclin A and Plk1. When the cell cycle
progresses to mid-late G1 phases, the accumulation of cyclin A
andPlk1 to a critical threshold (Hsu et al., 2002) leads to b-TRCP-
mediated ubiquitination and degradation of Cdh1 by sequential
phosphorylation of Cdh1 to create the b-TRCP-recognizable
phospho-degron(s). Because Cdh1 is one of the master regula-
tors of cell-cycle progression, the timely degradation of Cdh1
plays a critical role in determining the length of the G1 phase
(Robbins and Cross, 2010; Wa¨sch and Cross, 2002). To thisRCP in vitro. Autoradiograms showing recovery of 35S-labeled b-TRCP1 to the
h Plk1 before the in vitro pull-down assays. Where indicated, the GST-Cdh1
vo. (F) IB analysis of WCL derived from HeLa cells infected with the indicated
mg/ml puromycin for 72 hr to eliminate noninfected cells. (G) IB analysis ofWCL
ore harvesting.
nt. IB of WCL and anti-Cdh1 IP derived from HeLa cells (anti-HA was used as a
ght before harvesting for immunoblot analysis. Where indicated, the whole-cell
r146 and Plk binding motifs in Cdh1. (I) IB analysis of WCL derived from HeLa
tinfection, cells were selected with 1 mg/ml puromycin for 72 hr to eliminate
26S proteasome inhibitor MG132 (10 mM) for 12 hr before harvesting.
d from shCdh1- (or shGFP as a negative control) infected HeLa cells that are
before harvesting.
1- (or shGFP as a negative control) infected HeLa cells that are treated with the
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Figure 7. Schemes of the Cell-Cycle-Dependent Cdh1 Degradation by SCFb-TRCP
(A) A proposed model showing how priming phosphorylation of Cdh1 by the Cdk2/cyclin A kinase complex allows Plk1 to bind to Cdh1 and phosphorylate Cdh1
at Ser138 and Ser146. Phosphorylation of Cdh1 at Ser138 and Ser146 then triggers its interaction with, and subsequent ubiquitination by, SCFb-TRCP.
(B) Schematic illustration of the crosstalk between Cdh1 and its substrates cyclin A/Plk1 to influence the self-ubiquitination and SCFb-TRCP-mediated ubiquiti-
nation of Cdh1 in different cell-cycle phases. In early G1 phase, APC/Cdh1 actively degrades its substrates Plk1 and cyclin A. As a result, the abundance of both
cyclin A and Plk1 are kept low and Cdh1 mainly undergoes self-ubiquitination. On the other hand, when the cell cycle approaches the late G1 phase, the
accumulated Plk1 and cyclin A lead to increased phosphorylation of Cdh1, which leads to dissociation of Cdh1 from the APC core complex to terminate its E3
ligase activity and self-ubiquitination but, on the other hand, triggers its interaction with, and subsequent ubiquitination and degradation by, the SCFb-TRCP E3
ligase complex.
See also Figure S7.end, this bimodual regulation highlights the critical role of
b-TRCP in mediating APC/Cdh1’s ability to control the timing
of G1-S transition. Given that overexpression of both cyclin A
and Plk1 is frequently observed in human carcinomas (Liu
et al., 2008), these studies could provide a possible molecularFigure 6. SCFb-TRCP Negatively Regulates Cdh1 Stability to Ensure Pro
(A–C) Depletion of endogenous Plk1 or endogenous b-TRCP stabilizes Cdh1 and
constructs followed by selection with 1 mg/ml puromycin for 72 hr to eliminate non
and then released back into the cell cycle for immunoblot (IB) analysis (A). FACS
(D–F) Expression of nondegradable Cdh1 leads to a retarded S phase entry. H
expression of the indicated Cdh1 cDNA under the control of doxycycline. The
noninfected cells. Afterward, the resulting cell lines were arrested with nocodaz
exclude a possible indirect cell-cycle effect derived from aberrant overexpressio
adding nocodazole to induce the expression of WT-Cdh1 at levels comparable
approximately 3- to 4-fold over endogenous Cdh1 in part due to prolonged half-liv
to compare the inducible expression of the WT and mutant Cdh1 at the same exp
cycle distribution (F).
(G and H) Expression of nondegradable Cdh1 mutants enhances the cell-cycle
injected at 2-cell stage with variable amounts of mRNA encoding WT or S138A/
showing normal division or cell-cycle blockage phenotype as an example (G)
experiments were performed twice, with a total of 30–40 embryos injected for ea
See also Figure S6.mechanism for dysregulated cell cycle in pathological conditions
such as cancer and indicate that combined treatments using
Cdk2 and Plk1 inhibitors (for example, roscovitine and BI2536,
respectively) may have a synergistic effect in suppressing tumor
cell growth.per Cell-Cycle Progression
delays the S phase entry. HeLa cells were infected with the indicated shRNA
infected cells. Afterward, the resulting cell lines were arrested with nocodazole
was performed in (B) to monitor the changes of cell-cycle distribution (C).
eLa cells were infected with pTRIPZ lentiviral vectors that allow the ectopic
infected cells were selected with 1 mg/ml puromycin for 72 hr to eliminate
ole for 18 hr and then released back into the cell cycle for IB analysis (D). To
n of Cdh1, 100 ng/ml doxycycline was added to various cell lines 3 hr before
to endogenous Cdh1, whereas 4A and S138/S146A-Cdh1 were expressed
es (see also Figures S6C–S6F). The blots were probed and exposed identically
erimental condition. FACS was performed in (E) to monitor the changes of cell-
blockage phenotype of Xenopus embryos. Fertilized Xenopus embryos were
S146A-Cdh1. Pictures were taken at the indicated time points after injection,
. The percentage of cell-cycle blockage phenotype is quantified in (H). The
ch category.
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Previous studies have demonstrated that Cdh1 undergoes
self-ubiquitination in a D-box-dependent manner (Listovsky
et al., 2004). As Cdk2/cyclin-A- or Cdk1/cyclin-B-mediated
phosphorylation of Cdh1 terminates its E3 ligase activity (Peters,
2002), it is plausible that these phosphorylation events also
inhibit the self-ubiquitination of Cdh1. As complete degradation
of cyclin A and cyclin B is required for mitotic exit (Harper et al.,
2002; Peters, 2002), in the early G1 phase, both cyclin A and
cyclin B expression levels are low such that APC/Cdh1 E3 ligase
is mostly active, where the self-ubiquitination of Cdh1 should
primarily occur. On the other hand, with the progressive accu-
mulation of Cdh1 substrates including cyclin A and Plk1 in the
mid-late G1 phases, the degradation mechanism of Cdh1 is
shifted from self-ubiquitination to b-TRCP-mediated ubiquitina-
tion. Therefore, a nonphosphorylatable Cdh1 mutant (such as
4A or 6A-Cdh1) is defective in b-TRCP-mediated ubiquitination,
but instead may undergo constant self-ubiquitination.
Importantly, aberrant regulation of Cdh1 abundance has been
reported to result in severe cell-cycle defects. Depletion of Cdh1
in primary human fibroblasts led to premature senescence (Gao
et al., 2009a), whereas overexpressing Cdh1 leads to G1 cell-
cycle arrest coupled with endoreplication (Sørensen et al.,
2000). Given that Cdh1 expression levels are critical for proper
cell-cycle progression, our studies reveal that its stability is sub-
jected to tight regulation by both b-TRCP and self-ubiquitination.
Notably, the existence of multiple degradation mechanisms has
also been characterized for many other critical cell-cycle regula-
tors including p53 and p21 (Brooks andGu, 2011; Lu and Hunter,
2010). For more details, see also Extended Discussion.
EXPERIMENTAL PROCEDURES
Immunoblots and Immunoprecipitation
Cells were lysed in EBC buffer (50 mM Tris [pH 7.5], 120 mM NaCl, 0.5%
NP-40) supplemented with protease inhibitors (Complete Mini, Roche) and
phosphatase inhibitors (phosphatase inhibitor cocktail set I and II, Calbio-
chem). The protein concentrations of the lysates were measured using the
Bio-Rad protein assay reagent on a Beckman Coulter DU-800 spectropho-
tometer. The lysates were then resolved by SDS-PAGE and immunoblotted
with indicated antibodies. For immunoprecipitation, 800 mg lysates were incu-
bated with the appropriate antibody (1–2 mg) for 3–4 hr at 4C followed by 1 hr
incubation with Protein A Sepharose beads (GE Healthcare). Immunocom-
plexes were washed five times with NETN buffer (20 mM Tris [pH 8.0],
100 mM NaCl, 1 mM EDTA, and 0.5% NP-40) before being resolved by
SDS-PAGE and immunoblotted with indicated antibodies as described previ-
ously (Gao et al., 2011; Wan et al., 2011).
siRNA
As described previously, siRNA oligos were transfected into subconfluent cells
with oligofectamine or Lipofectamine 2000 (Invitrogen) according to the
manufacturer’s instructions (Wei et al., 2004). Human siRNA oligos against
Cdh1 have been described previously (Wei et al., 2004). A human siRNA oligo
that can deplete both b-TRCP1 and b-TRCP2 (sense, 50-AAGUGGAAUUU
GUGGAACAUC-30) has been validated previously (Jin et al., 2003). A human
siRNA oligo against Cullin 1 (sense, 50-GGUCGCUUCAUAAACAACATT-30 )
has been described and validated previously (Benmaamar and Pagano,
2005; Gao et al., 2010). E2F-1 scramble and Luciferase GL2 siRNA oligonucle-
otides were purchased from Dharmacon and served as negative controls.
Cell Culture and Synchronization
Cell culture, including synchronization and transfection, has been described
previously (Wei et al., 2004). For synchronization, HeLa cells were arrested814 Cell Reports 4, 803–816, August 29, 2013 ª2013 The Authorsin G2/Mphase in 330 nM nocodazole for 18 hr and thenwashedwith PBS three
times and replated into nocodazole-free fresh medium. The 293T cells engi-
neered to express a Cullin 1-deletion (Cul1-N252) in a doxycycline-inducible
manner were kind gifts from Dr. Michele Pagano (Benmaamar and Pagano,
2005). Lentiviral shRNA virus packaging and subsequent infection of various
cell lines were performed according to the protocol described previously
(Boehm et al., 2005). For cell viability assays, cells were plated at 10,000 per
well in 96-well plates, and incubated with appropriate medium containing
roscovitine (Cell Signaling), alone or in combination with Plk1 inhibitor
BI2536 (Selleckchem) for the indicated time period. Assays were performed
with CellTiter-Glo Luminescent Cell Viability Assay Kit according to the manu-
facturer’s instructions (Promega). Cycloheximide (CHX) experimentswere per-
formed as described previously (Gao et al., 2009b).
Xenopus Embryos and RNA Injection
The animals and procedures used in this study were in accordance with the
guidelines and approval of the Harvard Medical School Institutional Animal
Care and Use Committees. An Animal Welfare Assurance of Compliance is
on file with the Office of Laboratory Animal Welfare (OLAW) (#A3431-01).
Xenopus embryos culture and RNA injection were described previously (Kroll
et al., 1998). In brief, Xenopus embryos were obtained from previously unovu-
lated X. laevis frogs (NASCO) by in vitro fertilization, dejellied, and cultured at
16C–18C in 0.13Marc’s Modified Ringer’s solution (Peng, 1991) containing
50 mg/ml gentamicin. Embryos were staged according to Nieuwkoop and
Faber (1967). Embryos were injected with RNAs in 0.2 3 Marc’s Modified
Ringer’s solution containing 5% Ficoll and 50 mg/ml gentamicin and cultured
in the same media at 16C–18C. For more details, see also Extended Exper-
imental Procedures.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Extended Results, Extended Discussion,
Extended Experimental Procedures, and seven figures and can be found
with this article online at http://dx.doi.org/10.1016/j.celrep.2013.07.031.
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